ALDH7A1 and tuberculosis: The drug has also been studied in cutaneous lupus erythematosus, tuberculosis (TB) and HIV infection; published evidence in TB suggests that PDE inhibition can enhance the lung function recovery (Subbian et al., 2016; Wallis et al., 2021) and improve responsiveness to the antibacterial therapy (Subbian et al., 2016).